US20050130995A1 - Process for producing 4-aminoquinazoline compound - Google Patents

Process for producing 4-aminoquinazoline compound Download PDF

Info

Publication number
US20050130995A1
US20050130995A1 US10/503,664 US50366404A US2005130995A1 US 20050130995 A1 US20050130995 A1 US 20050130995A1 US 50366404 A US50366404 A US 50366404A US 2005130995 A1 US2005130995 A1 US 2005130995A1
Authority
US
United States
Prior art keywords
compound
reaction
organic solvent
formula
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/503,664
Inventor
Shigeyoshi Nishino
Kenji Hirotsu
Hidetaka Shima
Takashi Harada
Hiroyuki Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries Ltd filed Critical Ube Industries Ltd
Assigned to UBE INDUSTRIES, LTD. reassignment UBE INDUSTRIES, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARADA, TAKASHI, HIROTSU, KENJI, NISHINO, SHIGEYOSHI, ODA, HIROYUKI, SHIMA, HIDETAKA
Publication of US20050130995A1 publication Critical patent/US20050130995A1/en
Priority to US12/051,605 priority Critical patent/US20080177069A1/en
Priority to US12/400,895 priority patent/US8318932B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms

Definitions

  • the present invention relates to a process for preparing a 4-aminoquinazoline compound from a quinazolin-4-one compound.
  • the 4-aminoquinazoline compound is useful as an intermediate or a starting compound for preparing a pharmaceutically active compound or an agricultural chemical.
  • the invention specifically relates to a process for preparing 6-halogeno-4-arylaminoquinazoline from 6-halogenoquinazolin-4-one.
  • the invention further relates to a process for preparing 6-halogeno-4-chloroquinazoline from 6-halogenoquinazolin-4-one.
  • the 6-halogeno-4-chloroquinazoline is employable as a starting compound for preparing the 6-halogeno-4-arylaminoquinazoline.
  • JP-A-10-152477 describes a process for preparing a 4-arylaminoquinazoline compound from a quinazolin-4-one, which comprises the steps of chlorinating 4-iodoquinazolin-4-one using an excessive amount of oxalyl chloride to produce 6-iodo-4-chloroquinazoline (intermediate compound), concentrating the reaction product under reducing pressure to isolate the resulting product; reacting the 6-iodo-4-chloroquinazoline with 5-aminoindole to give 6-iodo-4-(5-indolylamino)quinazoline.
  • the yield is not high.
  • the intermediate compound i.e., 4-chloroquinazoline compound, shows no satisfactory stability in the presence of water and no satisfactory resistance to heat. Accordingly, the compound should be handled carefully.
  • WO 96/09294 describes a process for preparing 6-halogeno-4-chloroquinazoline from 6-halogenoquinazolin-4-one which comprises reacting the 6-halogenoquinazolin-4-one with an excessive amount of phosphorus oxychloride.
  • This process has problems in that a large amount of smelly phosphorus oxychloride should be used, yield of the reaction product (i.e., 6-halogeno-4-chloroquinazoline) is low, and a large amount of an organic solvent is necessarily employed for recovering the reaction product from an excessive amount of phosphorus oxychloride. Thus, complicated post-treating procedures are required.
  • the present invention has an object to provide a simple process for preparing a 4-aminoquinazoline compound from a quinazolin-4-one compound.
  • the invention specifically has an object to provide a process for preparing 6-halogeno-4-arylaminoquinazoline from 6-halogenoquinazolin-4-one.
  • the invention further relates has an object to provide a process for preparing 6-halogeno-4-chloroquinazoline from 6-halogenoquinazolin-4-one.
  • the 6-halogeno-4-chloroquinazoline is employable as a starting compound for preparing the 6-halogeno-4-arylaminoquinazoline.
  • the present invention resides in a process for preparing a 4-aminoquinazoline compound having the formula (3): in which each of R 1 , R 2 , R 3 and R 4 independently represents a group not participating the below-mentioned reaction, or R 1 , R 2 , R 3 and R 4 are combined to form a ring, and each of R 5 and R 6 independently represents a hydrogen atom or a hydrocarbyl group which can have a substituent, which comprises:
  • the invention further resides in the process wherein the quinazolin-4-one compound of formula (1) is 6-halogenoquinazolin-4-one of the following formula (4), the amine compound of formula (2) is arylamine of the following formula (5), and the 4-arylaminoquinazoline compound of formula (3) is 6-halogeno-4-arylaminoquinazoline of the following formula (6): in which X is a halogen atom, and Ar is an aryl group which can have a substituent.
  • the invention furthermore resides in a process for preparing 6-halogeno-4-chloroquinazoline having the formula (7): in which X is a halogen atom, which comprises reacting 6-halogenoquinazolin-4-one having the formula (4): in which X has the same meaning as above, with a chlorinating agent in an organic solvent in the presence of an organic base.
  • the quinazolin-4-one compound employed in the reaction of the invention as the starting compound is represented by the aforementioned formula (1).
  • each of R 1 , R 2 , R 3 and R 4 a group that can have a substituent, and does not participate in the reactions of the first and second steps.
  • the group is a hydrogen atom, an alkyl group having 1-12 carbon atoms, a cycloalkyl group having 1-12 carbon atoms, an aralkyl group having 7-15 carbon atoms, an aryl group having 6-14 carbon atoms, a halogen atom, an alkoxy group having 1-12 carbon atoms, an alkylthio group having 1-12 carbon atoms, an arylthio group having 6-14 carbon atoms, nitro, cyano, amino, carboxyl, ester groups, or amide.
  • R 1 , R 2 , R 3 and R 4 can be combined with each other to form a ring.
  • alkyl groups examples include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl. These groups can be any of isomers.
  • cycloalkyl groups examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • aralkyl groups examples include benzyl, phenethyl, and phenylpropyl. These groups can be any of isomers.
  • aryl groups examples include phenyl, p-tolyl, naphthyl, and anthryl. These groups can be any of isomers.
  • halogen atoms include fluorine, chlorine, bromine, and iodine.
  • alkoxy groups examples include methoxy, ethoxy, and propoxy. These groups can be any of isomers.
  • alkylthio groups examples include methylthio, ethylthio, and propylthio. These groups can be any of isomers.
  • arylthio groups examples include phenylthio, p-tolylthio, naphthylthio, and anthrylthio. These groups can be any of isomers.
  • ester groups examples include methoxycarbonyl, ethoxycarbonyl, and propoxycarbonyl. These groups can be any of isomers.
  • alkyl, cycloalkyl, aralkyl, aryl, alkoxy, alkylthio, arylthio, and amino may have a substituent.
  • substituents include a substituent bonded via a carbon atom, a substituent bonded via an oxygen atom, a substituent bonded via a nitrogen atom, a substituent bonded via a sulfur atom, and a halogen atom.
  • substituents bonded via a carbon atom include alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, and hexyl; cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; alkenyl groups such as vinyl, allyl, propenyl, cyclopropenyl, cyclobutenyl, and cyclopentenyl; heterocyclic alkenyl groups such as pyrrolidyl, pyrrolyl, furyl, and thienyl; aryl groups such as phenyl, tolyl, xylyl, biphenylyl, naphthyl, anthryl, and phenanthryl; acyl groups (possibly be acetallized) such as formyl, acetyl, propionyl, acryloyl, pivaloyl, cycloal
  • substituents bonded via an oxygen atom include hydroxyl; alkoxy groups such as methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, benzyloxy, piperidyloxy, and pyranyloxy; and aryloxy groups such as phenoxy, toluyloxy, and naphthyloxy. These groups can be any of isomers.
  • substituents bonded via a nitrogen atom include primary amino groups such as methylamino, ethylamino, butylamino, cyclohexylamino, phenylamino, and naphthylamino; secondary amino groups such as dimethylamino, diethylamino, dibutylamino, methylethylamino, methylbutylamino, and diphenylamino; heterocyclic amino groups such as morpholino, piperidino, piperazinyl, pyrazolidinyl, pyrrolidino, and indolyl; and imino. These groups can be any of isomers.
  • substituents bonded via a sulfur atom include mercapto; thioalkoxy groups such as thiomethoxy, thioethoxy, and thiopropoxy; and thioaryloxy groups such as thiophenoxy, thiotoluyloxy, and thionaphthyloxy. These groups can be any of isomers.
  • halogen atoms examples include fluorine, chlorine, bromine, and iodine.
  • R 5 is a hydrogen atom or a hydrocarbyl group which can have a substituent.
  • the hydrocarbyl groups include alkyl groups having 1-12 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, and hexyl; cycloalkyl groups such having 1-12 carbon atoms as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; aralkyl groups having 7-13 carbon atoms such as benzyl, phenethyl, and phenylpropyl; and aryl groups having 7-13 carbon atoms such as phenyl, tolyl, naphthyl, and anthryl. These groups can be any of isomers.
  • the above-mentioned hydrocarbyl group can have a substituent.
  • substituents are those described for R 1 , R 2 , R 3 and R 4 .
  • the organic base used in the reaction of the first step can be an aliphatic amine such as trimethylamine, triethylamine, ethyldiisopropylamine, or tributylamine; an aromatic amine such as dimethylaniline or diethylaniline; or a heterocyclic amine such as pyridine, quinoline, pyrimidine, or 4-dimethylaminopyridine.
  • Preferred is an aliphatic amine. More preferred is triethylamine.
  • the organic base can be used singly or in combination.
  • the organic base can be employed preferably in an amount of 0.8 to 2.5 moles, more preferably 1.0 to 1.5 moles, per one mole of the quinazolin-4-one compound.
  • organic solvent employed in the reaction of the first step there are no specific limitations with respect to the organic solvent employed in the reaction of the first step, so far as the solvent does not participate in the reaction.
  • examples are aliphatic hydrocarbons such as hexane, cyclohexane, and heptane; halogenated hydrocarbons such as chloroform and dichloroethane; aromatic hydrocarbons such as toluene, xylene, and mesitylene; halogenated aromatic hydrocarbons such as chlorobenzene; ethers such as diethyl ether, tetrahydrofuran, and dimethoxyethane; and amides such as N,N-dimethylformamide and 1,3-dimethylimidazolindione.
  • aromatic hydrocarbons More preferred is toluene.
  • the organic solvents can be employed singly or in combination. Further, the organic solvent can be placed in the reaction mixture while the reaction proceeds, if necessary.
  • the amount of the organic solvent employed in the reaction depends on the homogeneity and stirring condition of the reaction mixture. It is preferred that the solvent is employed in an amount of 0.5 to 30 g (more preferably 1 to 10 g, most preferably 1 to 5 g) per one gram of the quinazolin-4-one compound.
  • the chlorinating agent used in the reaction of the first step can be phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride, thionyl chloride, sulfuryl chloride, nitrosyl chloride, and chlorine molecule. Preferred is phosphorus oxychloride.
  • the chlorinating agent can be used singly or in combination.
  • the chlorinating agent is preferably employed in an amount of 0.9 to 7.0 moles, more preferably 1.0 to 5.0 moles, most preferably 1.0 to 2.5 moles per one mole of the quinazolin-4-one compound.
  • the organic solvent employed in the reaction of the second step there are no specific limitations with respect to the organic solvent employed in the reaction of the second step, so far as the solvent does not participate in the reaction.
  • the organic solvents include halogenated aliphatic hydrocarbons such as methylene chloride and chloroform; halogenated aromatic hydrocarbons such as chlorobenzene; nitrites such as acetonitrile and propionitrile; ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone, and methyl isobutyl ketone; and ethers such as diethyl ether, tetrahydrofuran, and dimethoxyethane.
  • ketones More preferred is methyl ethyl ketone.
  • the organic solvent can be used singly or in combination.
  • the amount of the organic solvent employed in the reaction depends on the homogeneity and stirring condition of the reaction mixture. It is preferred that the solvent is employed in an amount of 0.1 to 10 mL (more preferably 0.5 to 5 mL) per one gram of the quinazolin-4-one compound.
  • the amine compound used in the reaction of the second step of the invention is represented by the aforementioned formula (2).
  • the reactions of the process of the invention can be performed, for instance, by a first step in which a quinazolin-4-one compound, an organic base, a chlorinating agent, and an organic solvent are mixed and stirred in an inert gas atmosphere, and a second step in which the resulting reaction liquid is further stirred after addition of an organic solvent and an amine compound.
  • These reactions are preferably carried out at a temperature in the range of 10 to 150° C., more preferably 50 to 120° C., most preferably 40 to 100° C.
  • the combination of the first and second steps can give the main product, i.e., hydrochloride of a 4-aminoquinazoline compound, which can be neutralized with a base (e.g., aqueous alkali metal hydroxide) to give a free 4-aminoquinazoline compound.
  • a base e.g., aqueous alkali metal hydroxide
  • the 4-aminoquinazoline compound produced in the second step can be isolated and purified by the conventional procedures such as filtration, extraction, concentration, distillation, recrystallization, and column chromatography.
  • 6-halogeno-4-arylaminoquinazoline of formula (6) can be obtained by employing 6-halogenoquinazolin-4-one of formula (4) as the quinazolin-4-one compound and arylamine of formula (5) as the amine compound.
  • X is a halogen atom (fluorine, chlorine, bromine, or iodine). Preferred is iodine.
  • Ar in formulas (5) and (6) is an aryl group that can have a substituent. Examples of the aryl groups are carbon ring aromatic groups having 6-14 carbon atoms and heterocyclic aromatic groups such as phenyl, biphenylyl, naphthyl, anthryl, phenanthryl, pyridyl, quinolyl, pyrrolidyl, pyrrolyl, furyl, and thienyl.
  • substituents are substituents bonded via carbon atom, substituents bonded via oxygen atom, substituents bonded via nitrogen atom, substituents bonded via sulfur atom, and halogen atoms. There are no limitations with respect to number and position of the substituent.
  • 6-halogeno-4-arylaminoquinazoline hydrochloride is produced as a main product after the second step.
  • This product can be converted to free 6-halogeno-4-arylaminoquinazoline by neutralization with a base (e.g., aqueous alkali metal hydroxide).
  • a base e.g., aqueous alkali metal hydroxide.
  • 6-halogenoquinazolin-4-one of formula (4) When 6-halogenoquinazolin-4-one of formula (4) is employed as the starting compound in the first step, the main reaction product, i.e., 6-halogeno-4-chloroquinazoline can be isolated before it is processed in the second step.
  • 6-Halogeno-4-chloroquinazoline can be recovered as a crystalline product, for instance, by cooling the reaction liquid.
  • the reaction liquid is stirred preferably at ⁇ 10-70° C., more preferably at 0-30° C., after addition of an organic solvent, whereby a crystalline product precipitates.
  • the organic solvent can be halogenated aliphatic hydrocarbon such as methylene chloride or chloroform; halogenated aromatic hydrocarbon such as chlorobenzene; nitrites such as acetonitrile or propionitrile, ketone such as acetone, methyl ethyl ketone, methyl isopropyl ketone, or methyl isobutyl ketone; or ether such as diethyl ether, tetrahydrofuran, or dimethoxyethane.
  • ketone More preferred is methyl ethyl ketone.
  • the organic solvent can be used singly or in combination.
  • the amount of the organic solvent depends on the homogeneity and stirring condition of the reaction mixture. It is preferred that the organic solvent is employed in an amount of 0.1 to 10 mL (more preferably 0.5 to 5 mL) per one gram of the 6-halogenoquinazolin-4-one.
  • the crystalline product of 6-halogeno-4-chloroquinazoline can be further purified by stirring the product in aqueous alkali metal hydroxide to remove impurities (e.g., organic base hydrochloride).
  • impurities e.g., organic base hydrochloride
  • 6-Methyl-4-(3-chloro-4-methoxy)anilinoquinazoline had the following physical properties.
  • the crystalline product was collected by filtration, washed with 30 mL of water, and dried under reduced pressure, to give 2.26 g (isolated yield: 84%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-benzylaminoquinazoline as a yellowish crystalline product.
  • 6-Iodo-4-benzylaminoquinazoline had the following physical properties.
  • Example I-3 The procedures of Example I-3 were repeated except for replacing benzylamine with 1.13 g (13.3 mmol) of piperidine, to give 2.26 g (isolated yield: 79%, purity 87% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-piperidinoquinazoline as a yellowish crystalline product.
  • 6-Iodo-4-piperidinoquinazoline had the following physical properties.
  • 6-Iodo-4-anilinoquinazoline had the following physical properties.
  • Example II-1 The procedures of Example II-1 were repeated except that acetone was replaced with methyl isobutyl ketone and that 753 mg (8.1 mmol) of aniline was used, to give 1.90 g (isolated yield: 74%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-anilinoquinazoline.
  • Example II-1 The procedures of Example II-1 were repeated except for replacing aniline with 1.39 g (8.8 mmol) of 3-chloro-4-methoxyaniline, to give 2.92 g (isolated yield: 96%, purity 96% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline as a yellowish crystalline product.
  • 6-Iodo-4-(3-chloro-4-methoxy)anilinoquinazoline had the following physical properties.
  • Example II-3 The procedures of Example II-3 were repeated except that acetone was replaced with methyl isobutyl ketone and that 1.28 g (8.1 mmol) of 3-chloro-4-methoxyaniline was used, to give 2.55 g (isolated yield: 84%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline.
  • Example II-1 The procedures of Example II-1 were repeated except that acetone was replaced with methyl isobutyl ketone and that aniline was replaced with 1.18 g (8.1 mmol) of 3-chloro-4-fluoroaniline, to give 2.45 g (isolated yield: 83%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-(3-chloro-4-fluoro)anilinoquinazoline as a pale yellow crystalline product.
  • 6-Iodo-4-(3-chloro-4-fluoro)anilinoquinazoline had the following physical properties.
  • the crystalline product was collected by filtration, washed with 500 mL of water and 20 mL of acetonitrile, and dried under reduced pressure, to give 18.0 g (isolated yield: 98%, purity 100% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]quinazoline as a yellowish crystalline product.
  • 6-Iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-quinazoline had the following physical properties.
  • the crystalline product was collected by filtration, washed with 50 mL of water and 5 mL of acetonitrile, and dried under reduced pressure, to give 2.28 g (isolated yield: 71%, purity 89% in terms of area percentage determined by high performance liquid chromatography) of 4-(3-chloro-4-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline as a sallowish crystalline product.
  • 6-halogeno-4-chloroquinazoline was reacted with methanol to give 6-halogeno-4-methoxyquinazoline quantitatively, which was then analyzed by high performance liquid chromatography.
  • 6-Iodo-4-chloroquinazoline had the following physical properties.
  • Example IV-2 The procedures of Example IV-2 were repeated except that 1.80 g (11.8 mmol) of phosphorus oxychloride was used and that 1.19 g (11.8 mmol) of triethylamine was used. There was produced 2.11 g (reaction yield: 99%) of 6-iodo-4-chloroquinazoline.
  • Example IV-2 The procedures of Example IV-2 were repeated except that 2.48 g (16.2 mmol) of phosphorus oxychloride was used and that 1.64 g (16.2 mmol) of triethylamine was used. There was produced 2.14 g (reaction yield: 100%) of 6-iodo-4-chloroquinazoline.
  • Example IV-2 The procedures of Example IV-2 were repeated except that the reaction temperature was changed to 55° C. There was produced 2.05 g (reaction yield: 96%) of 6-iodo-4-chloroquinazoline.
  • Example IV-2 The procedures of Example IV-2 were repeated except that the reaction temperature was changed to 95° C. There was produced 2.09 g (reaction yield: 98%) of 6-iodo-4-chloroquinazoline.
  • Example IV-4 The procedures of Example IV-4 were repeated except for replacing triethylamine with 1.96 g (16.2 mmol) of N,N-dimethylaniline. There was produced 1.92 g (reaction yield: 90%) of 6-iodo-4-chloroquinazoline.
  • Example IV-4 The procedures of Example IV-4 were repeated except for replacing triethylamine with 1.28 g (16.2 mmol) of pyridine. There was produced 1.96 g (reaction yield: 92%) of 6-iodo-4-chloroquinazoline.
  • Example IV-9 The procedures of Example IV-9 were repeated except for replacing acetone with methyl ethyl ketone. There was produced 44.9 g (isolated yield: 84%) of 6-iodo-4-chloroquinazoline.
  • Example IV-9 The procedures of Example IV-9 were repeated except for replacing acetone with methyl isopropyl ketone. There was produced 48.6 g (isolated yield: 91%) of 6-iodo-4-chloroquinazoline.
  • Example IV-9 The procedures of Example IV-9 were repeated except for replacing acetone with acetonitrile. There was produced 48.1 g (isolated yield: 90%) of 6-iodo-4-chloroquinazoline.
  • Example IV-9 The procedures of Example IV-9 were repeated except for replacing acetone with chloroform. There was produced 48.1 g (isolated yield: 90%) of 6-iodo-4-chloroquinazoline.
  • Example IV-9 The procedures of Example IV-9 were repeated except for replacing acetone with tetrahydrofuran. There was produced 47.6 g (isolated yield: 89%) of 6-iodo-4-chloroquinazoline.
  • Example IV-1 The procedures of Example IV-1 were repeated except for replacing toluene with chlorobenzene. There was produced 48.1 g (isolated yield: 90%) of 6-iodo-4-chloroquinazoline.
  • Example IV-1 The procedures of Example IV-1 were repeated except that the stirring temperature after completion of the reaction was changed from 0° C. to 25° C. There was produced 45.4 g (isolated yield: 85%) of 6-iodo-4-chloroquinazoline.
  • Example IV-10 The procedures of Example IV-10 were repeated except that the stirring temperature after completion of the reaction was changed from 0° C. to 25° C. There was produced 44.9 g (isolated yield: 84%) of 6-iodo-4-chloroquinazoline.
  • Example IV-9 The procedures of Example IV-9 were repeated except that acetone was replaced with methyl isopropyl ketone and that the stirring temperature after completion of reaction was changed from 0° C. to 25° C. There was produced 47.0 g (isolated yield: 88%) of 6-iodo-4-chloroquinazoline.
  • Example IV-9 The procedures of Example IV-9 were repeated except that acetone was replaced with methyl isobutyl ketone and that the stirring temperature after completion of reaction was changed from 0° C. to 25° C. There was produced 44.9 g (isolated yield: 84%) of 6-iodo-4-chloroquinazoline.
  • 4-aminoquinazoline compounds can be produced from quinazolin-4-one compounds by simple procedures.
  • 6-halogeno-4-arylaminoquinazoline can be produced from 6-halogenoquinazolin-4-one by simple procedures.
  • the invention provides processes for producing 6-iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]quinazoline, 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline, and 4-(3-chloro-4-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline.
  • These compounds are of value as intermediate compounds for preparing pharmaceuticals showing excellent pharmacological functions.

Abstract

A 4-aminoquinazoline derivative can be obtained by the steps of reacting quinazolin-4-one or its derivative with a chlorinating agent in a first organic solvent in the presence of an organic base, and subsequently reacting the reaction product with an amine compound represented by the formula R5—NH—R6 (each of R5 and R6 represents hydrogen or an optionally substituted hydrocarbyl group) in the presence of a second organic solvent.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a process for preparing a 4-aminoquinazoline compound from a quinazolin-4-one compound. The 4-aminoquinazoline compound is useful as an intermediate or a starting compound for preparing a pharmaceutically active compound or an agricultural chemical.
  • The invention specifically relates to a process for preparing 6-halogeno-4-arylaminoquinazoline from 6-halogenoquinazolin-4-one.
  • The invention further relates to a process for preparing 6-halogeno-4-chloroquinazoline from 6-halogenoquinazolin-4-one. The 6-halogeno-4-chloroquinazoline is employable as a starting compound for preparing the 6-halogeno-4-arylaminoquinazoline.
  • BACKGROUND OF THE INVENTION
  • JP-A-10-152477 describes a process for preparing a 4-arylaminoquinazoline compound from a quinazolin-4-one, which comprises the steps of chlorinating 4-iodoquinazolin-4-one using an excessive amount of oxalyl chloride to produce 6-iodo-4-chloroquinazoline (intermediate compound), concentrating the reaction product under reducing pressure to isolate the resulting product; reacting the 6-iodo-4-chloroquinazoline with 5-aminoindole to give 6-iodo-4-(5-indolylamino)quinazoline. Unfortunately, the yield is not high. Further, it should be noted that the intermediate compound, i.e., 4-chloroquinazoline compound, shows no satisfactory stability in the presence of water and no satisfactory resistance to heat. Accordingly, the compound should be handled carefully.
  • WO 96/09294 describes a process for preparing 6-halogeno-4-chloroquinazoline from 6-halogenoquinazolin-4-one which comprises reacting the 6-halogenoquinazolin-4-one with an excessive amount of phosphorus oxychloride. This process, however, has problems in that a large amount of smelly phosphorus oxychloride should be used, yield of the reaction product (i.e., 6-halogeno-4-chloroquinazoline) is low, and a large amount of an organic solvent is necessarily employed for recovering the reaction product from an excessive amount of phosphorus oxychloride. Thus, complicated post-treating procedures are required.
  • DISCLOSURE OF THE INVENTION
  • The present invention has an object to provide a simple process for preparing a 4-aminoquinazoline compound from a quinazolin-4-one compound.
  • The invention specifically has an object to provide a process for preparing 6-halogeno-4-arylaminoquinazoline from 6-halogenoquinazolin-4-one.
  • The invention further relates has an object to provide a process for preparing 6-halogeno-4-chloroquinazoline from 6-halogenoquinazolin-4-one. The 6-halogeno-4-chloroquinazoline is employable as a starting compound for preparing the 6-halogeno-4-arylaminoquinazoline.
  • The present invention resides in a process for preparing a 4-aminoquinazoline compound having the formula (3):
    Figure US20050130995A1-20050616-C00001

    in which each of R1, R2, R3 and R4 independently represents a group not participating the below-mentioned reaction, or R1, R2, R3 and R4 are combined to form a ring, and each of R5 and R6 independently represents a hydrogen atom or a hydrocarbyl group which can have a substituent, which comprises:
      • a first step of reacting a quinazolin-4-one compound having the formula (1):
        Figure US20050130995A1-20050616-C00002

        in which R1, R2, R3 and R4 have the same meaning as above, with a chlorinating agent in a first organic solvent in the presence of an organic base, and
      • a second step for reacting a reaction product of the first step with an amine compound having the formula (2):
        R5—NH—R6  (2)
        in which R5 and R6 have the same meaning as above, in the presence of a second organic solvent.
  • The invention further resides in the process wherein the quinazolin-4-one compound of formula (1) is 6-halogenoquinazolin-4-one of the following formula (4), the amine compound of formula (2) is arylamine of the following formula (5), and the 4-arylaminoquinazoline compound of formula (3) is 6-halogeno-4-arylaminoquinazoline of the following formula (6):
    Figure US20050130995A1-20050616-C00003

    in which X is a halogen atom, and Ar is an aryl group which can have a substituent.
  • The invention furthermore resides in a process for preparing 6-halogeno-4-chloroquinazoline having the formula (7):
    Figure US20050130995A1-20050616-C00004

    in which X is a halogen atom,
    which comprises reacting 6-halogenoquinazolin-4-one having the formula (4):
    Figure US20050130995A1-20050616-C00005

    in which X has the same meaning as above,
    with a chlorinating agent in an organic solvent in the presence of an organic base.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The quinazolin-4-one compound employed in the reaction of the invention as the starting compound is represented by the aforementioned formula (1). In formula (1), each of R1, R2, R3 and R4 a group that can have a substituent, and does not participate in the reactions of the first and second steps. For example, the group is a hydrogen atom, an alkyl group having 1-12 carbon atoms, a cycloalkyl group having 1-12 carbon atoms, an aralkyl group having 7-15 carbon atoms, an aryl group having 6-14 carbon atoms, a halogen atom, an alkoxy group having 1-12 carbon atoms, an alkylthio group having 1-12 carbon atoms, an arylthio group having 6-14 carbon atoms, nitro, cyano, amino, carboxyl, ester groups, or amide. R1, R2, R3 and R4 can be combined with each other to form a ring.
  • Examples of the alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl. These groups can be any of isomers.
  • Examples of the cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Examples of the aralkyl groups include benzyl, phenethyl, and phenylpropyl. These groups can be any of isomers.
  • Examples of the aryl groups include phenyl, p-tolyl, naphthyl, and anthryl. These groups can be any of isomers.
  • Examples of halogen atoms include fluorine, chlorine, bromine, and iodine.
  • Examples of the alkoxy groups include methoxy, ethoxy, and propoxy. These groups can be any of isomers.
  • Examples of the alkylthio groups include methylthio, ethylthio, and propylthio. These groups can be any of isomers.
  • Examples of the arylthio groups include phenylthio, p-tolylthio, naphthylthio, and anthrylthio. These groups can be any of isomers.
  • Examples of the ester groups include methoxycarbonyl, ethoxycarbonyl, and propoxycarbonyl. These groups can be any of isomers.
  • The above-mentioned alkyl, cycloalkyl, aralkyl, aryl, alkoxy, alkylthio, arylthio, and amino may have a substituent. Examples of the substituents include a substituent bonded via a carbon atom, a substituent bonded via an oxygen atom, a substituent bonded via a nitrogen atom, a substituent bonded via a sulfur atom, and a halogen atom.
  • Examples of the substituents bonded via a carbon atom include alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, and hexyl; cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; alkenyl groups such as vinyl, allyl, propenyl, cyclopropenyl, cyclobutenyl, and cyclopentenyl; heterocyclic alkenyl groups such as pyrrolidyl, pyrrolyl, furyl, and thienyl; aryl groups such as phenyl, tolyl, xylyl, biphenylyl, naphthyl, anthryl, and phenanthryl; acyl groups (possibly be acetallized) such as formyl, acetyl, propionyl, acryloyl, pivaloyl, cyclohexylcarbonyl, benzoyl, naphthoyl, and toluoyl; carboxyl groups; alkoxycarbonyl groups such as methoxycarbonyl and ethoxycarbonyl; aryloxycarbonyl groups such as phenoxycarbonyl; halogenated alkyl groups such as trifluoromethyl; and cyano. These groups can be any of isomers.
  • Examples of the substituents bonded via an oxygen atom include hydroxyl; alkoxy groups such as methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, benzyloxy, piperidyloxy, and pyranyloxy; and aryloxy groups such as phenoxy, toluyloxy, and naphthyloxy. These groups can be any of isomers.
  • Examples of the substituents bonded via a nitrogen atom include primary amino groups such as methylamino, ethylamino, butylamino, cyclohexylamino, phenylamino, and naphthylamino; secondary amino groups such as dimethylamino, diethylamino, dibutylamino, methylethylamino, methylbutylamino, and diphenylamino; heterocyclic amino groups such as morpholino, piperidino, piperazinyl, pyrazolidinyl, pyrrolidino, and indolyl; and imino. These groups can be any of isomers.
  • Examples of the substituents bonded via a sulfur atom include mercapto; thioalkoxy groups such as thiomethoxy, thioethoxy, and thiopropoxy; and thioaryloxy groups such as thiophenoxy, thiotoluyloxy, and thionaphthyloxy. These groups can be any of isomers.
  • Examples of the halogen atoms include fluorine, chlorine, bromine, and iodine.
  • R5 is a hydrogen atom or a hydrocarbyl group which can have a substituent. Examples of the hydrocarbyl groups include alkyl groups having 1-12 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, and hexyl; cycloalkyl groups such having 1-12 carbon atoms as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; aralkyl groups having 7-13 carbon atoms such as benzyl, phenethyl, and phenylpropyl; and aryl groups having 7-13 carbon atoms such as phenyl, tolyl, naphthyl, and anthryl. These groups can be any of isomers.
  • The above-mentioned hydrocarbyl group can have a substituent. Examples of the substituents are those described for R1, R2, R3 and R4.
  • The organic base used in the reaction of the first step can be an aliphatic amine such as trimethylamine, triethylamine, ethyldiisopropylamine, or tributylamine; an aromatic amine such as dimethylaniline or diethylaniline; or a heterocyclic amine such as pyridine, quinoline, pyrimidine, or 4-dimethylaminopyridine. Preferred is an aliphatic amine. More preferred is triethylamine. The organic base can be used singly or in combination.
  • The organic base can be employed preferably in an amount of 0.8 to 2.5 moles, more preferably 1.0 to 1.5 moles, per one mole of the quinazolin-4-one compound.
  • There are no specific limitations with respect to the organic solvent employed in the reaction of the first step, so far as the solvent does not participate in the reaction. Examples are aliphatic hydrocarbons such as hexane, cyclohexane, and heptane; halogenated hydrocarbons such as chloroform and dichloroethane; aromatic hydrocarbons such as toluene, xylene, and mesitylene; halogenated aromatic hydrocarbons such as chlorobenzene; ethers such as diethyl ether, tetrahydrofuran, and dimethoxyethane; and amides such as N,N-dimethylformamide and 1,3-dimethylimidazolindione. Preferred are aromatic hydrocarbons. More preferred is toluene. The organic solvents can be employed singly or in combination. Further, the organic solvent can be placed in the reaction mixture while the reaction proceeds, if necessary.
  • The amount of the organic solvent employed in the reaction depends on the homogeneity and stirring condition of the reaction mixture. It is preferred that the solvent is employed in an amount of 0.5 to 30 g (more preferably 1 to 10 g, most preferably 1 to 5 g) per one gram of the quinazolin-4-one compound.
  • The chlorinating agent used in the reaction of the first step can be phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride, thionyl chloride, sulfuryl chloride, nitrosyl chloride, and chlorine molecule. Preferred is phosphorus oxychloride. The chlorinating agent can be used singly or in combination.
  • The chlorinating agent is preferably employed in an amount of 0.9 to 7.0 moles, more preferably 1.0 to 5.0 moles, most preferably 1.0 to 2.5 moles per one mole of the quinazolin-4-one compound.
  • There are no specific limitations with respect to the organic solvent employed in the reaction of the second step, so far as the solvent does not participate in the reaction. Examples of the organic solvents include halogenated aliphatic hydrocarbons such as methylene chloride and chloroform; halogenated aromatic hydrocarbons such as chlorobenzene; nitrites such as acetonitrile and propionitrile; ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone, and methyl isobutyl ketone; and ethers such as diethyl ether, tetrahydrofuran, and dimethoxyethane. Preferred are ketones. More preferred is methyl ethyl ketone. The organic solvent can be used singly or in combination.
  • The amount of the organic solvent employed in the reaction depends on the homogeneity and stirring condition of the reaction mixture. It is preferred that the solvent is employed in an amount of 0.1 to 10 mL (more preferably 0.5 to 5 mL) per one gram of the quinazolin-4-one compound.
  • The amine compound used in the reaction of the second step of the invention is represented by the aforementioned formula (2).
  • The reactions of the process of the invention can be performed, for instance, by a first step in which a quinazolin-4-one compound, an organic base, a chlorinating agent, and an organic solvent are mixed and stirred in an inert gas atmosphere, and a second step in which the resulting reaction liquid is further stirred after addition of an organic solvent and an amine compound. These reactions are preferably carried out at a temperature in the range of 10 to 150° C., more preferably 50 to 120° C., most preferably 40 to 100° C. There are no specific limitations with respect to the reaction pressure.
  • The combination of the first and second steps can give the main product, i.e., hydrochloride of a 4-aminoquinazoline compound, which can be neutralized with a base (e.g., aqueous alkali metal hydroxide) to give a free 4-aminoquinazoline compound.
  • The 4-aminoquinazoline compound produced in the second step can be isolated and purified by the conventional procedures such as filtration, extraction, concentration, distillation, recrystallization, and column chromatography.
  • As described above, 6-halogeno-4-arylaminoquinazoline of formula (6) can be obtained by employing 6-halogenoquinazolin-4-one of formula (4) as the quinazolin-4-one compound and arylamine of formula (5) as the amine compound.
  • In formulas (4) and (6), X is a halogen atom (fluorine, chlorine, bromine, or iodine). Preferred is iodine. Ar in formulas (5) and (6) is an aryl group that can have a substituent. Examples of the aryl groups are carbon ring aromatic groups having 6-14 carbon atoms and heterocyclic aromatic groups such as phenyl, biphenylyl, naphthyl, anthryl, phenanthryl, pyridyl, quinolyl, pyrrolidyl, pyrrolyl, furyl, and thienyl.
  • Examples of the substituents are substituents bonded via carbon atom, substituents bonded via oxygen atom, substituents bonded via nitrogen atom, substituents bonded via sulfur atom, and halogen atoms. There are no limitations with respect to number and position of the substituent.
  • When the compound of formula (4) and the compound of formula (6) are employed as the starting compounds, 6-halogeno-4-arylaminoquinazoline hydrochloride is produced as a main product after the second step. This product can be converted to free 6-halogeno-4-arylaminoquinazoline by neutralization with a base (e.g., aqueous alkali metal hydroxide). Thus obtained 6-halogeno-4-arylaminoquinazoline can be isolated and purified by the conventional procedures such as filtration, extraction, concentration, distillation, recrystallization, and column chromatography.
  • When 6-halogenoquinazolin-4-one of formula (4) is employed as the starting compound in the first step, the main reaction product, i.e., 6-halogeno-4-chloroquinazoline can be isolated before it is processed in the second step.
  • 6-Halogeno-4-chloroquinazoline can be recovered as a crystalline product, for instance, by cooling the reaction liquid. However, it is preferred that the reaction liquid is stirred preferably at −10-70° C., more preferably at 0-30° C., after addition of an organic solvent, whereby a crystalline product precipitates.
  • The organic solvent can be halogenated aliphatic hydrocarbon such as methylene chloride or chloroform; halogenated aromatic hydrocarbon such as chlorobenzene; nitrites such as acetonitrile or propionitrile, ketone such as acetone, methyl ethyl ketone, methyl isopropyl ketone, or methyl isobutyl ketone; or ether such as diethyl ether, tetrahydrofuran, or dimethoxyethane. Preferred is ketone. More preferred is methyl ethyl ketone. The organic solvent can be used singly or in combination.
  • The amount of the organic solvent depends on the homogeneity and stirring condition of the reaction mixture. It is preferred that the organic solvent is employed in an amount of 0.1 to 10 mL (more preferably 0.5 to 5 mL) per one gram of the 6-halogenoquinazolin-4-one.
  • The crystalline product of 6-halogeno-4-chloroquinazoline can be further purified by stirring the product in aqueous alkali metal hydroxide to remove impurities (e.g., organic base hydrochloride).
  • EXAMPLE I-1 Preparation of 4-(3-chloro-4-fluoro)anilinoquinazoline
  • In a 20 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 0.80 g (5.5 mmol) of quinazolin-4-one, 1.00 g (6.6 mmol) of phosphorus oxychloride, and 10 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 0.66 g (6.6 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C. and then reaction was carried out for 2 hours. Subsequently, the mixture was cooled to room temperature, and 1.6 mL of methyl isobutyl ketone and 0.96 g (6.6 mmol) of 3-chloro-4-fluoroaniline were added. The resulting mixture was again heated to 75° C., and then reaction was carried out under stirring for one hour. After the reaction was complete, the reaction mixture was cooled to room temperature, and thus precipitated crystalline product was collected by filtration. Subsequently, the crystal-line product was placed in 30 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 30 minutes at room temperature. The crystalline product was collected by filtration, washed with 30 mL of water, and dried under reduced pressure, to give 1.35 g (isolated yield: 89%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 4-(3-chloro-4-fluoro)anilinoquinazoline as a yellowish crystalline product.
  • 4-(3-Chloro-4-fluoro)anilinoquinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 7.46 (1H, t, J=9.0 Hz), 7.64-7.70 (1H, m), 7.81-7.92 (3H, m), 8.23 (1H, dd, J=6.6, 2.4 Hz), 8.53 (1H, d, J=8.1 Hz), 8.66 (1H, s), 9.90 (1H, s)
  • CI-MS (m/e): 274 (M+1)
  • EXAMPLE I-2 Preparation of 6-methyl-4-(3-chloro-4-methoxy)anilinoquinazoline
  • In a 20 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 0.80 g (5.0 mmol) of 6-methylquinazolin-4-one, 0.92 g (6.0 mmol) of phosphorus oxychloride, and 5 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 0.61 g (6.0 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C., and then reaction was carried out for 2 hours. Subsequently, the mixture was cooled to room temperature, and 1.6 mL of methyl isobutyl ketone and 0.94 g (6.0 mmol) of 3-chloro-4-methoxyaniline were added. The resulting mixture was again heated to 75° C. and then reaction was carried out under stirring for one hour. After the reaction was complete, the reaction mixture was cooled to room temperature, and thus precipitated crystalline product was collected by filtration. Subsequently, the crystalline product was placed in 30 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 30 minutes at room temperature. The crystalline product was collected by filtration, washed with 30 mL of water, and dried under reduced pressure, to give 1.36 g (isolated yield: 91%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-methyl-4-(3-chloro-4-methoxy)anilinoquinazoline as a yellowish crystalline product.
  • 6-Methyl-4-(3-chloro-4-methoxy)anilinoquinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 3.87 (3H, d, J=9.0 Hz) 7.47 (1H, dd, J=8.7, 1.8 Hz), 7.58 (1H, s), 7.75 (1H, dd, J=9.0, 2.4 Hz), 8.03 (1H, d, J=2.7 Hz), 8.40 (1H, d, J=8.4 Hz), 8.55 (1H, s), 9.68 (1H, s)
  • CI-MS (m/e): 300 (M+1)
  • EXAMPLE I-3 Preparation of 6-iodo-4-benzylaminoquinazoline
  • In a 20 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 2.0 g (7.4 mmol) of 6-iodoquinazolin-4-one, 1.35 g (8.8 mmol) of phosphorus oxychloride, and 10 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 0.66 g (6.6 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C., and then reaction was carried out for 2 hours. Subsequently, the mixture was cooled to room temperature, and 3 mL of methyl isobutyl ketone and 3.15 g (29.4 mmol) of benzylamine were added. The resulting mixture was again heated to 75° C., and then reaction was carried out under stirring for one hour. After the reaction was complete, the reaction mixture was cooled to room temperature. Thus precipitated crystalline product was collected by filtration. Subsequently, the crystalline product was placed in 30 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 30 minutes at room temperature. The crystalline product was collected by filtration, washed with 30 mL of water, and dried under reduced pressure, to give 2.26 g (isolated yield: 84%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-benzylaminoquinazoline as a yellowish crystalline product.
  • 6-Iodo-4-benzylaminoquinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 4.77 (2H, d, J=5.7 Hz), 7.22-7.39 (5H, m), 7.47 (1H, d, J=8.7 Hz), 8.03 (1H, dd, J=9.0, 1.8 Hz), 8.48 (1H, s), 8.80 (1H, d, J=1.5 Hz), 8.99 (1H, t, J=5.4 Hz)
  • CI-MS (m/e): 362 (M+1)
  • EXAMPLE I-4 Preparation of 6-iodo-4-piperidinoquinazoline
  • The procedures of Example I-3 were repeated except for replacing benzylamine with 1.13 g (13.3 mmol) of piperidine, to give 2.26 g (isolated yield: 79%, purity 87% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-piperidinoquinazoline as a yellowish crystalline product.
  • 6-Iodo-4-piperidinoquinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 1.6-1.7 (6H, m), 3.6-3.7 (4H, m), 7.56 (1H, d, J=8.7 Hz), 8.04 (1H, dd, J=8.7, 1.8 Hz), 8.21 (1H, d, J=1.8 Hz), 8.60 (1H, s)
  • CI-MS (m/e): 340 (M+1)
  • EXAMPLE II-1 Preparation of 6-iodo-4-anilinoquinazoline
  • In a 20 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 2.00 g (7.35 mmol) of 6-iodoquinazolin-4-one, 1.35 g (8.8 mmol) of phosphorus oxychloride, and 6 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 0.89 g (8.8 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C., and then reaction was carried out for 2 hours. Subsequently, the mixture was cooled to room temperature, and 3 mL of acetone and 821 mg (8.8 mmol) of aniline were added. The resulting mixture was again heated to 75° C., and then reaction was carried out under stirring for one hour. After the reaction was complete, the reaction mixture was cooled to room temperature, and thus precipitated crystalline product was collected by filtration. Subsequently, the crystalline product was placed in 30 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 30 minutes at room temperature. The crystalline product was collected by filtration, washed with 30 mL of water, and dried under reduced pressure, to give 1.91 g (isolated yield: 73%, purity 97% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-anilinoquinazoline as a yellowish crystalline product.
  • 6-Iodo-4-anilinoquinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 7.12-7.18 (1H, m), 7.37-7.44 (2H, m), 7.56 (1H, d, J=8.7 Hz), 7.82-7.88 (2H, m), 8.12 (1H, dd, J=2.1, 8.7 Hz), 8.61 (1H, s), 9.01 (1H, d, J=1.8 Hz), 9.87 (1H, s)
  • CI-MS (m/e): 348 (M+1)
  • EXAMPLE II-2 Preparation of 6-iodo-4-anilinoquinazoline
  • The procedures of Example II-1 were repeated except that acetone was replaced with methyl isobutyl ketone and that 753 mg (8.1 mmol) of aniline was used, to give 1.90 g (isolated yield: 74%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-anilinoquinazoline.
  • EXAMPLE II-3 Preparation of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline
  • The procedures of Example II-1 were repeated except for replacing aniline with 1.39 g (8.8 mmol) of 3-chloro-4-methoxyaniline, to give 2.92 g (isolated yield: 96%, purity 96% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline as a yellowish crystalline product.
  • 6-Iodo-4-(3-chloro-4-methoxy)anilinoquinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 3.88 (3H, s), 7.20 (1H, d, J=9.3 Hz), 7.55 (1H, d, J=8.7 Hz), 7.75 (1H, dd, J=2.7, 9.0 Hz), 8.00 (1H, d, J=2.7 Hz), 8.10 (1H, dd, J=2.1, 8.7 Hz), 8.61 (1H, s), 8.96 (1H, d, J=1.8 Hz), 9.83 (1H, s)
  • CI-MS (m/e): 412 (M+1)
  • EXAMPLE II-4 Preparation of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline
  • In a 500 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 51.7 g (190 mmol) of 6-iodoquinazolin-4-one, 35.0 g (228 mmol) of phosphorus oxychloride, and 153 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 23.1 g (228 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C., and then reaction was carried out for 2 hours. Subsequently, the mixture was cooled to room temperature, and 51 mL of methyl ethyl ketone was added. The resulting mixture was stirred for 10 minutes. Then, the mixture was again heated to 75° C., while 40.0 g (228 mmol) of 3-chloro-4-methoxyaniline was slowly added. The resulting mixture was stirred for 2 hours at the same temperature after addition of 250 mL of toluene and 150 mL of methyl ethyl ketone. After the reaction was complete, the reaction mixture was cooled to room temperature, and thus precipitated crystalline product was collected by filtration. Subsequently, the crystalline product was placed in 300 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 30 minutes at room temperature. The crystalline product was collected by filtration, washed with 500 mL of water, and dried under reduced pressure, to give 73.4 g (isolated yield: 94%, purity 99.5% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline as a yellowish crystalline product.
  • EXAMPLE II-5 Preparation of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline
  • The procedures of Example II-3 were repeated except that acetone was replaced with methyl isobutyl ketone and that 1.28 g (8.1 mmol) of 3-chloro-4-methoxyaniline was used, to give 2.55 g (isolated yield: 84%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-(3-chloro-4-methoxy)anilinoquinazoline.
  • EXAMPLE II-6 Preparation of 6-iodo-4-(3-chloro-4-fluoro)anilinoquinazoline
  • The procedures of Example II-1 were repeated except that acetone was replaced with methyl isobutyl ketone and that aniline was replaced with 1.18 g (8.1 mmol) of 3-chloro-4-fluoroaniline, to give 2.45 g (isolated yield: 83%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-(3-chloro-4-fluoro)anilinoquinazoline as a pale yellow crystalline product.
  • 6-Iodo-4-(3-chloro-4-fluoro)anilinoquinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 7.46 (1H, t, J=9.0 Hz), 7.59 (1H, d, J=8.7 Hz), 7.82-7.87 (1H, m), 8.12-8.21 (2H, m), 8.66 (1H, s), 8.96 (1H, d, J=2.1 Hz), 9.95 (1H, s)
  • CI-MS (m/e): 400 (M+1)
  • EXAMPLE III-1 Preparation of 6-iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]quinazoline
  • In a 200 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 9.80 g (36 mmol) of 6-iodoquinazolin-4-one, 6.63 g (43 mmol) of phosphorus oxychloride, and 30 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 4.41 g (8.8 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C., and then reaction was carried out at 70-80° C. for 3 hours. Subsequently, the mixture was cooled to room temperature, and 40 mL of acetonitrile and 11.8 mg (43 mmol) of 3-chloro-4-(3-fluorobenzyloxy)aniline were added. The resulting mixture was stirred at 70-80° C. for 2 hours. After the reaction was complete, the reaction mixture was cooled to room temperature, and thus precipitated crystalline product was collected by filtration and washed with 20 mL of acetonitrile. Subsequently, the crystalline product was placed in 80 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 2 hours at room temperature. The crystalline product was collected by filtration, washed with 500 mL of water and 20 mL of acetonitrile, and dried under reduced pressure, to give 18.0 g (isolated yield: 98%, purity 100% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]quinazoline as a yellowish crystalline product.
  • 6-Iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-quinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 5.26 (2H, s), 7.16-7.22 (1H, m), 7.26-7.35 (3H, m), 7.44-7.51 (1H, m), 7.56 (1H, d, J=8.8 Hz), 7.75 (1H, dd, J=9.0, 2.4 Hz), 8.03 (1H, s), 8.12 (1H, d, J=8.8 Hz), 8.61 (1H, s), 8.96 (1H, s), 9.85 (1H, s)
  • CI-MS (m/e): 506 (M+1)
  • EXAMPLE III-2 Preparation of 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride
  • In a 50 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 4.08 g (13.9 mmol) of 6,7-bis(2-methoxy)quinazolin-4-one, 2.55 g (16.7 mmol) of phosphorus oxychloride, 3.37 g (33.4 mmol) of triethylamine and 12 mL of toluene in a nitrogen atmosphere. The resulting mixture was heated at 70-80° C. for 3 hours. Subsequently the mixture was cooled to room temperature, and 1.94 g (16.7 mmol) of 3-ethynylaniline was added. The resulting mixture was then stirred at 70-80° C. for 2 hours. Subsequently, the mixture was stirred at room temperature after addition of 16 mL of acetonitrile. After the reaction was complete, the precipitated crystalline product was collected by filtration, washed with 8 mL of cooled acetonitrile, and dried under reduced pressure, to give 6.75 g (isolated yield: 88%, purity 78.1% in terms of area percentage determined by high performance liquid chromatography) of 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride as yellow solid.
  • 6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 3.63 (2H, s), 3.78-3.80 (4H, m), 4.28 (1H, s), 4.33-4.41 (4H, m), 7.39-7.52 (3H, m), 7.80 (1H, d, J=8.1 Hz), 7.89 (1H, s), 8.46 (1H, s), 8.85 (1H, brs), 11.60 (1H, s), 14.9 (1H, brs)
  • CI-MS (m/e): 394 (M+1)
  • EXAMPLE III-3 Preparation of 4-(3-chloro-4-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline
  • In a 50 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 2.00 g (6.3 mmol) of 6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-one, 1.19 g (7.6 mmol) of phosphorus oxychloride, 0.76 g (6.3 mmol) of triethylamine, and 8 mL of toluene in a nitrogen atmosphere. The mixture was then stirred at 70-80° C. for 3 hours. Subsequently, the mixture was cooled to room temperature, and 1.09 g (6.3 mmol) of 3-chloro-4-fluoroaniline and 6 mL of toluene were added. The resulting mixture was stirred at 110° C. for 10 hours. Further, the mixture was stirred at room temperature after addition of 8 mL of acetonitrile. After the reaction was complete, the precipitated crystalline product was collected by filtration, and washed with 5 mL of cooled acetonitrile. Subsequently, the crystalline product was placed in 16 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 4 hours at room temperature. The crystalline product was collected by filtration, washed with 50 mL of water and 5 mL of acetonitrile, and dried under reduced pressure, to give 2.28 g (isolated yield: 71%, purity 89% in terms of area percentage determined by high performance liquid chromatography) of 4-(3-chloro-4-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline as a sallowish crystalline product.
  • 4-(3-Chloro-4-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline had the following physical properties.
  • 1H-NMR (DMSO-d6, δ (ppm)): 1.93-2.00 (2H, m), 2.36-2.51 (6H, m), 3.57-3.60 (4H, m), 3.97 (3H, s), 4.19-4.21 (2H, m), 7.20 (1H, s), 7.42-7.48 (1H, m), 7.78-7.84 (2H, m), 8.13 (1H, dd, J=6.8, 2.7 Hz), 8.50 (1H, s), 9.56 (1H, s)
  • CI-MS (m/e): 447 (M+1)
  • EXAMPLE IV-1 Preparation of 6-iodo-4-chloroquinazoline
  • In a 100 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 20.0 g (73.5 mmol) of 6-iodoquinazolin-4-one, 13.5 g (88.2 mmol) of phosphorus oxychloride, and 60 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 8.92 g (88.2 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C., and the reaction was carried out for 2 hours. After the reaction was complete, the reaction mixture was cooled to 0° C. and stirred for one hour. Thus precipitated pale yellow crystalline product of 6-iodo-4-chloroquinazoline was collected by filtration. Subsequently, the crystalline product was placed in 100 mL of aqueous sodium hydroxide (1 mol/L), and the aqueous mixture was stirred for 30 minutes at room temperature. The crystalline product was collected by filtration, washed with 120 mL of water, and dried under reduced pressure, to give 19.3 g (isolated yield: 90%, purity 99.3% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-chloroquinazoline as a yellowish crystalline product.
  • The analysis of 6-halogeno-4-chloroquinazoline in the reaction mixture was performed by the following procedures: After the reaction was complete, 6-halogeno-4-chloroquinazoline was reacted with methanol to give 6-halogeno-4-methoxyquinazoline quantitatively, which was then analyzed by high performance liquid chromatography.
  • 6-Iodo-4-chloroquinazoline had the following physical properties.
  • 1H-NMR (CDCl3, δ (ppm)): 7.80 (1H, d, J=7.8 Hz), 8.20 (1H, dd, J=2.1, 9.0 Hz), 8.65 (1H, d, J=2.1 Hz), 9.06 (1H, s)
  • CI-MS (m/e): 291 (M+1)
  • EXAMPLE IV-2 Preparation of 6-iodo-4-chloroquinazoline
  • In a 20 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 2.00 g (7.35 mmol) of 6-iodoquinazolin-4-one, 1.24 g (8.09 mmol) of phosphorus oxychloride, and 10 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 0.82 g (8.09 mmol) of triethylamine was slowly added. The resulting mixture was heated to 75° C., and the reaction was carried out for 2 hours. After the reaction was complete, the reaction mixture was cooled to room temperature, and 100 mL of methanol was added. The mixture was stirred for 15 minutes at the same temperature, to give 6-iodo-4-methoxyquinazoline. Analysis of the reaction mixture by high performance liquid chromatography indicated that 2.11 g (reaction yield: 99%) of 6-iodo-4-chloroquinazoline was produced.
  • EXAMPLE IV-3 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-2 were repeated except that 1.80 g (11.8 mmol) of phosphorus oxychloride was used and that 1.19 g (11.8 mmol) of triethylamine was used. There was produced 2.11 g (reaction yield: 99%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-4 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-2 were repeated except that 2.48 g (16.2 mmol) of phosphorus oxychloride was used and that 1.64 g (16.2 mmol) of triethylamine was used. There was produced 2.14 g (reaction yield: 100%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-5 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-2 were repeated except that the reaction temperature was changed to 55° C. There was produced 2.05 g (reaction yield: 96%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-6 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-2 were repeated except that the reaction temperature was changed to 95° C. There was produced 2.09 g (reaction yield: 98%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-7 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-4 were repeated except for replacing triethylamine with 1.96 g (16.2 mmol) of N,N-dimethylaniline. There was produced 1.92 g (reaction yield: 90%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-8 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-4 were repeated except for replacing triethylamine with 1.28 g (16.2 mmol) of pyridine. There was produced 1.96 g (reaction yield: 92%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-9 Preparation of 6-iodo-4-chloroquinazoline
  • In a 500 mL-volume glass vessel equipped with a stirrer, a thermometer and a reflux condenser were placed 50.0 g (184 mmol) of 6-iodoquinazolin-4-one, 33.8 g (221 mmol) of phosphorus oxychloride, and 300 mL of toluene in a nitrogen atmosphere. While the mixture was stirred at room temperature, 22.3 g (221 mmol) of triethylamine was slowly added. The resulting mixture was heated at 60° C. for 30 minutes and then heated at 75° C. for 2 hours, for carrying out reaction. After the reaction was complete, the reaction mixture was cooled to room temperature, and 50 mL of acetone was added. The mixture was then cooled to 0° C. and stirred for 30 minutes. Thus precipitated pale yellow crystalline product of 6-iodo-4-chloroquinazoline was collected by filtration. Subsequently, the crystalline product was placed in 200 mL of water, and 9 mL of aqueous sodium hydroxide (1 mol/L) was added. The aqueous mixture (pH 10-11) was stirred for 30 minutes at room temperature. The crystalline product was collected by filtration, washed successively with 100 mL of acetone, 200 mL of water and 100 mL of acetone, and dried at 60° C. under reduced pressure, to give 47.4 g (isolated yield: 89%, purity 99% in terms of area percentage determined by high performance liquid chromatography) of 6-iodo-4-chloroquinazoline as a yellowish crystalline product.
  • EXAMPLE IV-10 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-9 were repeated except for replacing acetone with methyl ethyl ketone. There was produced 44.9 g (isolated yield: 84%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-11 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-9 were repeated except for replacing acetone with methyl isopropyl ketone. There was produced 48.6 g (isolated yield: 91%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-12 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-9 were repeated except for replacing acetone with acetonitrile. There was produced 48.1 g (isolated yield: 90%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-13 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-9 were repeated except for replacing acetone with chloroform. There was produced 48.1 g (isolated yield: 90%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-14 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-9 were repeated except for replacing acetone with tetrahydrofuran. There was produced 47.6 g (isolated yield: 89%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-15 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-1 were repeated except for replacing toluene with chlorobenzene. There was produced 48.1 g (isolated yield: 90%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-16 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-1 were repeated except that the stirring temperature after completion of the reaction was changed from 0° C. to 25° C. There was produced 45.4 g (isolated yield: 85%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-17 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-10 were repeated except that the stirring temperature after completion of the reaction was changed from 0° C. to 25° C. There was produced 44.9 g (isolated yield: 84%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-18 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-9 were repeated except that acetone was replaced with methyl isopropyl ketone and that the stirring temperature after completion of reaction was changed from 0° C. to 25° C. There was produced 47.0 g (isolated yield: 88%) of 6-iodo-4-chloroquinazoline.
  • EXAMPLE IV-19 Preparation of 6-iodo-4-chloroquinazoline
  • The procedures of Example IV-9 were repeated except that acetone was replaced with methyl isobutyl ketone and that the stirring temperature after completion of reaction was changed from 0° C. to 25° C. There was produced 44.9 g (isolated yield: 84%) of 6-iodo-4-chloroquinazoline.
  • UTILIZATION IN INDUSTRY
  • According to the invention, 4-aminoquinazoline compounds can be produced from quinazolin-4-one compounds by simple procedures. Further, 6-halogeno-4-arylaminoquinazoline can be produced from 6-halogenoquinazolin-4-one by simple procedures. Furthermore, the invention provides processes for producing 6-iodo-4-[3-chloro-4-(3-fluorobenzyloxy)anilino]quinazoline, 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline, and 4-(3-chloro-4-fluoroanilino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline. These compounds are of value as intermediate compounds for preparing pharmaceuticals showing excellent pharmacological functions.

Claims (24)

1. A process for preparing a 4-aminoquinazoline compound having the formula (3):
Figure US20050130995A1-20050616-C00006
in which each of R1, R2, R3 and R4 independently represents a group not participating the below-mentioned reaction, or R1, R2, R3 and R4 are combined to form a ring, and each of R5 and R6 independently represents a hydrogen atom or a hydrocarbyl group which can have a substituent, which comprises:
a first step of reacting a quinazolin-4-one compound having the formula (1):
Figure US20050130995A1-20050616-C00007
in which R1, R2, R3 and R4 have the same meaning as above, with a chlorinating agent in a first organic solvent in the presence of an organic base, and
a second step for reacting a reaction product of the first step with an amine compound having the formula (2):

R5—NH—R6  (2)
in which R5 and R6 have the same meaning as above, in the presence of a second organic solvent.
2. The process of claim 1, wherein each of R1, R4 and R6 is hydrogen, each of R2 and R3 is 2-methoxyethoxy, and R5 is 3-ethynylphenyl.
3. The process of claim 1, wherein each of R1, R4 and R6 is hydrogen, R2 is methoxy, R3 is 3-morpholinopropoxy, and R5 is 3-chloro-4-fluorophenyl.
4. The process of claim 1, wherein the quinazolin-4-one compound of formula (1) is 6-halogenoquinazolin-4-one of the following formula (4), the amine compound of formula (2) is arylamine of the following formula (5), and the 4-arylaminoquinazoline compound of formula (3) is 6-halogeno-4-arylaminoquinazoline of the following formula (6):
Figure US20050130995A1-20050616-C00008
in which X is a halogen atom, and Ar is an aryl group which can have a substituent.
5. The process of claim 4, wherein X is iodine.
6. The process of claim 5, wherein Ar is 3-chloro-4-(3-fluorobenzyloxy)phenyl.
7. The process of claim 1, wherein the reaction of the first step is performed by adding the organic base to a mixture of the quinazolin-4-one compound, first organic solvent, and chlorinating agent.
8. The process of claim 1, wherein the organic base is used in an amount of 0.8 to 2.5 moles, based on one mole of the quinazolin-4-one compound.
9. The process of claim 1, wherein the first organic solvent is an aliphatic hydrocarbon, a halogenated aliphatic hydrocarbon, an aromatic hydrocarbon, a halogenated aromatic hydrocarbon, ether, or amide.
10. The process of claim 1, wherein the first organic solvent is an aromatic hydrocarbon.
11. The process of claim 1, wherein the chlorinating agent is phosphorus oxychloride.
12. The process of claim 1, wherein the chlorinating agent is used in an amount of 1.0 to 2.5 moles, based on one mole of the quinazolin-4-one compound.
13. The process of claim 1, wherein the second organic solvent is a halogenated aliphatic hydrocarbon, a halogenated aromatic hydrocarbon, nitrile, ketone, or ether.
14. The process of claim 1, wherein each of the reactions of the first and second steps is performed at a temperature of 10 to 150° C.
15. The process of claim 1, wherein the reaction product of the first step is subjected to the second step without isolating the reaction product from a reaction mixture of the first step.
16. A process for preparing 6-halogeno-4-chloroquinazoline having the formula (7):
Figure US20050130995A1-20050616-C00009
in which X is a halogen atom,
which comprises reacting 6-halogenoquinazolin-4-one having the formula (4):
Figure US20050130995A1-20050616-C00010
in which X has the same meaning as above,
with a chlorinating agent in an organic solvent in the presence of an organic base.
17. The process of claim 16, wherein X is iodine.
18. The process of claim 16, wherein the reaction is performed by adding the organic base to a mixture of the quinazolin-4-one compound, organic solvent, and chlorinating agent.
19. The process of claim 16, wherein the organic base is used in an amount of 0.8 to 2.5 moles, based on one mole of the quinazolin-4-one compound.
20. The process of claim 16, wherein the organic solvent is an aliphatic hydrocarbon, a halogenated aliphatic hydrocarbon, an aromatic hydrocarbon, a halogenated aromatic hydrocarbon, ether, or amide.
21. The process of claim 16, wherein the first organic solvent is an aromatic hydrocarbon.
22. The process of claim 16, wherein the chlorinating agent is phosphorus oxychloride.
23. The process of claim 16, wherein the chlorinating agent is used in an amount of 1.0 to 2.5 moles, based on one mole of the quinazolin-4-one compound.
24. The process of claim 16, wherein the reaction is performed at a temperature of 10 to 150° C.
US10/503,664 2002-02-06 2003-02-06 Process for producing 4-aminoquinazoline compound Abandoned US20050130995A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/051,605 US20080177069A1 (en) 2002-02-06 2008-03-19 Process for producing 4-aminoquinazoline compound
US12/400,895 US8318932B2 (en) 2002-02-06 2009-03-10 Process for producing 4-aminoquinazoline compound

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2002029745 2002-02-06
JP2002-29745 2002-02-06
JP2002-246656 2002-08-27
JP2002246656 2002-08-27
JP2002272892 2002-09-19
JP2002272893 2002-09-19
JP2002-272893 2002-09-19
JP2002-272892 2002-09-19
PCT/JP2003/001254 WO2003066602A1 (en) 2002-02-06 2003-02-06 Process for producing 4-aminoquinazoline compound

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/051,605 Continuation US20080177069A1 (en) 2002-02-06 2008-03-19 Process for producing 4-aminoquinazoline compound
US12/400,895 Continuation US8318932B2 (en) 2002-02-06 2009-03-10 Process for producing 4-aminoquinazoline compound

Publications (1)

Publication Number Publication Date
US20050130995A1 true US20050130995A1 (en) 2005-06-16

Family

ID=27739271

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/503,664 Abandoned US20050130995A1 (en) 2002-02-06 2003-02-06 Process for producing 4-aminoquinazoline compound
US12/051,605 Abandoned US20080177069A1 (en) 2002-02-06 2008-03-19 Process for producing 4-aminoquinazoline compound
US12/400,895 Expired - Fee Related US8318932B2 (en) 2002-02-06 2009-03-10 Process for producing 4-aminoquinazoline compound

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/051,605 Abandoned US20080177069A1 (en) 2002-02-06 2008-03-19 Process for producing 4-aminoquinazoline compound
US12/400,895 Expired - Fee Related US8318932B2 (en) 2002-02-06 2009-03-10 Process for producing 4-aminoquinazoline compound

Country Status (6)

Country Link
US (3) US20050130995A1 (en)
EP (1) EP1481971B1 (en)
JP (1) JP4389205B2 (en)
AT (1) ATE533750T1 (en)
AU (1) AU2003207291A1 (en)
WO (1) WO2003066602A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096881A1 (en) * 2003-09-19 2008-04-24 Astrazeneca Ab Quinazoline Derivatives
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090286982A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Novel salt-554
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
US7709640B2 (en) 2000-11-01 2010-05-04 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US20100152442A1 (en) * 2002-03-28 2010-06-17 Astrazeneca Ab 4-anilino quinazoline derivatives as antiproliferative agents
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221245D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256781A (en) * 1991-10-24 1993-10-26 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5661147A (en) * 1993-09-03 1997-08-26 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
US5747798A (en) * 1996-07-19 1998-05-05 Hughey & Phillips, Inc. Photocell checker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DE69709319T2 (en) * 1996-03-05 2002-08-14 Astrazeneca Ab 4-ANILINOQUINAZOLINE DERIVATIVES
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2351699T3 (en) 1999-02-10 2011-02-09 Astrazeneca Ab DERIVATIVES OF QUINAZOLINA AS INHIBITORS OF THE ANGIOGENESIS AND INTERMEDIATES OF THE SAME.
DE19911509A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256781A (en) * 1991-10-24 1993-10-26 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5661147A (en) * 1993-09-03 1997-08-26 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
US5747798A (en) * 1996-07-19 1998-05-05 Hughey & Phillips, Inc. Photocell checker

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43098E1 (en) 2000-11-01 2012-01-10 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US8536184B2 (en) 2000-11-01 2013-09-17 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US7709640B2 (en) 2000-11-01 2010-05-04 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US20100240893A1 (en) * 2000-11-01 2010-09-23 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
US8399667B2 (en) 2002-03-28 2013-03-19 Astrazeneca Ab 4-anilino quinazoline derivatives as antiproliferative agents
US20100152442A1 (en) * 2002-03-28 2010-06-17 Astrazeneca Ab 4-anilino quinazoline derivatives as antiproliferative agents
US8318752B2 (en) 2003-09-19 2012-11-27 Astrazeneca Ab 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
US20080096881A1 (en) * 2003-09-19 2008-04-24 Astrazeneca Ab Quinazoline Derivatives
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8404839B2 (en) 2008-05-13 2013-03-26 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A
US20090286982A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Novel salt-554
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Also Published As

Publication number Publication date
EP1481971B1 (en) 2011-11-16
WO2003066602A1 (en) 2003-08-14
AU2003207291A1 (en) 2003-09-02
US20090171083A1 (en) 2009-07-02
ATE533750T1 (en) 2011-12-15
JP4389205B2 (en) 2009-12-24
US8318932B2 (en) 2012-11-27
EP1481971A4 (en) 2006-03-08
US20080177069A1 (en) 2008-07-24
JPWO2003066602A1 (en) 2005-05-26
EP1481971A1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
US8318932B2 (en) Process for producing 4-aminoquinazoline compound
JP4631703B2 (en) Method for producing pyrimidin-4-one compound
JP5152680B2 (en) Process for producing alkoxyhalogenoalkoxyanthranilic acid derivatives
WO2007138613A2 (en) A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
JP2010209071A (en) Process for preparation of 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
US7232903B2 (en) Process for producing quinazolin-4-one and derivatives thereof
WO2005070909A1 (en) An improved process for the preparation of gefitinib
US8173806B2 (en) Method for production of quinazolin-4-one derivative
CN107098863B (en) Preparation method of gefitinib
JP3740835B2 (en) Process for producing 6,7-disubstituted-2,4-dioxoquinazoline
US20070270589A1 (en) Quinazoline Derivative and Process for Producing the Same
JP4661786B2 (en) Method for producing 4-aminopyrimidine compound
CN110204490B (en) Preparation method of disubstituted 4-chloroquinoline-3-carbonitrile derivative and bosutinib
CN115010671A (en) One-step synthesis method of 2-substituted quinazolinone
WO2003064377A1 (en) 4,5-substituted-2-formylaminobenzamides and processes for their production and conversion
JP2003212862A (en) Method for producing quinazolin-4-one derivative
JP2006143631A (en) Method for preparing 4-substituted pyrimidine compound

Legal Events

Date Code Title Description
AS Assignment

Owner name: UBE INDUSTRIES, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NISHINO, SHIGEYOSHI;HIROTSU, KENJI;SHIMA, HIDETAKA;AND OTHERS;REEL/FRAME:016399/0410

Effective date: 20040802

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION